A Swiss CBD company claims to have become the first cannabidiol firm to use liposomes to deliver the substance into users’ bodies.

Cibdol, based in Liestal, near Basel, says its range of products, launched in December, will enter the user’s system as much as four times quicker than traditional oils and capsules.

Liposomes, which have most notably been used for some cancer treatments, are microscopic pockets made from the same material as cell membranes which can be filled with medicines, drugs, and vitamins.

Because they are made from a substance extensively found in cells – phospholipids – they penetrate directly into tissue and cell walls, and can pass directly into a patient’s bloodstream.

Read full article
I'm already a subscriber
Author default picture


This article was written by one of CannIntelligence’s international correspondents. We currently employ more than 40 reporters around the world to cover individual cannabis and cannabinoid markets. For a full list, please see our Who We Are page.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization